PSYCHOPHARMACOLOGY OF BORDERLINE PERSONALITY DISORDER
Section snippets
DEFINITIONS: BPD AS A SYNDROMAL DISORDER
BPD is not a disease. It is a syndromal disorder defined by dysregulated temperament and maladaptive character. The symptom domains of BPD may be divided into cognitive-perceptual symptoms, affective dysregulation, impulsive-behavioral dyscontrol, and interpersonal psychopathology. Cognitive-perceptual symptoms in BPD are those stress-related, micropsychotic distortions in thinking, and perception which first gave this syndrome its borderline (e.g., borderline psychotic) appelation. Affective
CLINICAL PRESENTATIONS IN BPD
BPD was an early focus for pharmacologic intervention because of the clinical seriousness of the patient's symptomatic presentations, the high morbidity and mortality associated with the disorder. Suicide attempts are reported in as many as 73% of borderline patients admitted to inpatient hospital, with an average of 3.4 (±2.9) lifetime attempts per patient.51 Similar rates are reported in outpatient settings.66 With a completed suicide rate of 3% to 9.5%, BPD is one of the most lethal of
Background
Borderline disorders historically encompassed a spectrum of clinical presentations including both affective and schizotypal subtypes. Terms such as borderline, pseudoneurotic, or pseudopsychopathic schizophrenia, and latent and larval psychosis illustrate some of the diagnoses used to define the patient with BPD, “at the psychotic border,” (i.e., the patient with BPD characterized by odd-thinking and a vulnerability to brief, stress-related micro-psychotic episodes. Over the many iterations of
Background
The prominence of depressive moods and affective lability in the core pathology of BPD suggests a role for antidepressant medication. Some authors consider BPD, as currently defined, to be a subaffective disorder, or a temperament related to affective spectrum disorders.1 Comorbidity with Axis I affective disorders is highly prevalent in BPD, adding further clinical justification to the consideration of antidepressant medications. However, it is often unclear whether the depressed borderline
Background
Brief, reactive episodes of rage, affective and behavioral dyscontrol are among the core characteristics of BPD. Transient experiences of derealization, depersonalization, illusions, hallucinations, and other perceptual distortions also are commonly reported. These transient distortions in perception, mood and impulse bear a superficial resemblance to symptoms commonly found in temporal lobe epilepsy. Neurologically minded psychiatrists, noting the resemblance, postulated a limbic system cause
Background
The mood lability of the borderline patient provides a rationale for the empirical use of lithium carbonate, a medication highly effective against mood lability in bipolar disorders. Early empirical trials with patients termed emotionally unstable character disorder (EUCD) (DSM–II) demonstrated efficacy against mood lability.43 These patients were histrionic, adolescent girls with impulsive behaviors and hedonistic abuse of drugs and alcohol. Although there is some controversy as to whether
Background
Anxiety is a common presenting complaint in patients with BPD. Although the diathesis to disruptive anxiety may be a chronic trait in the borderline patient, (historically called “pan-anxiety” or “free-floating” anxiety), the symptom presentation is most often acute and reactive to clear interpersonal stressors such as perceived rejection, or abandonment issues. In this setting, many clinicians rely on rapid acting benzodiazepine anxiolytics to treat both the acute presentations and the
PUTTING IT ALL TOGETHER: A SYMPTOM-SPECIFIC APPROACH
Target symptoms for pharmacotherapy of the borderline patient can be divided into three domains: cognitive-perceptual symptoms, affective dysregulation, and impulsive-behavioral dyscontrol. Clinical treatment algorithms may be developed for each symptom domain using the available empirical literature.54 Although based on a small empiric database, algorithms for treatment of the BPD patient can offer initial guidance to the clinician.
Cognitive-perceptual symptoms include: suspiciousness,
CONCLUSION
- 1
Pharmacotherapy should be viewed as an adjuvant to psychotherapy in the treatment of the borderline patient (i.e., diminishing cognitive-perceptual, affective, and impulsive-behavioral symptom severity). Much of borderline psychopathology lies in the interpersonal domain, beyond the scope of medication management. Effective pharmacotherapy may make it possible for the patient to engage productively in psychotherapy; however, medications do not cure character and are never a substitute for
References (66)
Sub-affective disorders: Dysthymic, cyclothymic and bipolar II disorders in the “borderline” realm
Psychiatr Clin North Am
(1981)- et al.
Clozapine treatment of borderline patients: A preliminary study
Compr Psychiatry
(1993) - et al.
CSF metabolites in borderline personality disorder compared with normal controls
Biol Psychiatry
(1990) - et al.
Intravenous procaine as a probe of limbic system activity in psychiatric patients and normal controls
Biol Psychiatry
(1987) - et al.
Pharmacologic prevention of suicidal behavior
J Affect Disord
(1982) Fluoxetine in borderline personality disorder
Prog Neuropsychopharmacol Biol Psychiatry
(1989)Contemporary shift in the borderline concept from a subschizophrenic disorder to a subaffective disorder
Psychiatr Clin North Am
(1979)- et al.
Long-term use of lithium in aggressive disorders
Compr Psychiatry
(1973) - et al.
Low dose neuroleptic regimens in the treatment of borderline patients
Arch Gen Psychiatry
(1979)
Cerebrospinal fluid correlates of suicide attempts and aggression
Ann NY Acad Sci
The successful use of clozapine in ameliorating severe self mutilation in a patient with borderline personality disorder
J Personal Disord
Clonazepam in acute and maintenance treatment of bipolar affective disorder
J Clin Psych
A psychobiological model of temperament and character
Arch Gen Psychiatry
The Neuropsychopharmacology of Personality Disorders
Serotonergic studies in patients with affective and personality disorders: Correlates with suicidal and impulsive aggressive behavior
Arch Gen Psychiatry
Fluoxetine treatment of impulsive aggression in DSM III-R personality disorder patients
J Clin Psychopharmacol
Fluoxetine and Impulsive-Aggressive behavior in personality disordered subjects
Arch Gen Psychiatry
Fluoxetine trial in borderline personality disorder
Psychopharm Bull
Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine
Am J Psychiatry
Pharmacotherapy of borderline personality disorder: Alprazolam, carbamazepine, trifluoperazine and tranylcypromine
Arch Gen Psychiatry
A trial of carbamazepine in borderline personality disorder
Eur Neuropsychopharmacol
Brain glucose metabolism in borderline personality disorder
J Psychiatr Res
Temporal glucose metabolism in borderline personality disorder
Psychiatry Research Neuroimaging
Divalproex treatment of disruptive adolescents: A report of 10 cases
J Clin Psychiatry
The positive effect of alprazolam in the treatment of three patients with borderline personality disorder
Am J Psychiatry
Clonazepam: (1986) A novel therapeutic adjunct
Int J Psychiatry Med
Alprazolam induced dyscontrol in borderline personality disorder
Am J Psychiatry
Development of melancholia during carbamazepine treatment in borderline personality disorder
J Clin Psychopharmacol
Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder
Am J Psychiatry
Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo
Arch Gen Psychiatry
Prediction of change in borderline personality disorder
Psychopharmacol Bull
An open, noncomparative study of amoxapine in borderline disorders
Acta Psychiatr Scand
Cited by (144)
Personality disorders
2012, Handbook of Clinical NeurologyCitation Excerpt :Placebo-controlled studies have provided evidence for the efficacy of selective serotonin reuptake inhibitors (SSRIs) on rapid mood shifts, anger, and anxiety (Markovitz et al., 1991; Salzman et al., 1995; Coccaro and Kavoussi, 1997; Rinne et al., 2002). The possible toxic effects (e.g., after overdose), the potential worsening of cognitive-perceptual symptoms by tricyclic antidepressants, and the difficulties in managing borderline patients on monoamine oxidase inhibitors could lead clinicians to consider SSRIs as first-line agents in the treatment of the depressed, anxious, labile, and angry patient (Soloff, 2000). Another option is mood stabilizers.
HALF IN LOVE WITH DEATH: Managing the Chronically Suicidal Patient, Second Edition
2023, Half in Love with Death: Managing the Chronically Suicidal Patient, Second EditionBorderline Personality Disorder in the Courtroom
2021, Psychiatry, Psychology and LawAll the faces of research on borderline personality pathology: Drawing future trajectories through a network and cluster analysis of the literature
2020, Journal of Evidence-Based Psychotherapies
Address reprint requests to Paul H. Soloff, MD, Western Psychiatric Institute and Clinic, 3811 O'Hara Street, Pittsburgh, PA 15213
- *
Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh, Pittsburgh, Pennsylvania